BRI2 ectodomain affects Aβ fibrillation and tau truncation in human neuroblastoma cells

Campo, M.; Oliveira, C.; Scheper, W.; Zwart, R.; Korth, C.; Müller-Schiffmann, A.; Kostallas, G.; Biverstal, H.; Presto, J.; Johansson, J.; Hoozemans, J.; Pereira, C.; Teunissen, C.
April 2015
Cellular & Molecular Life Sciences;Apr2015, Vol. 72 Issue 8, p1599
Academic Journal
Alzheimer's disease (AD) is pathologically characterized by the presence of misfolded proteins such as amyloid beta (Aβ) in senile plaques, and hyperphosphorylated tau and truncated tau in neurofibrillary tangles (NFT). The BRI2 protein inhibits Aβ aggregation via its BRICHOS domain and regulates critical proteins involved in initiating the amyloid cascade, which has been hypothesized to be central in AD pathogenesis. We recently detected the deposition of BRI2 ectodomain associated with Aβ plaques and concomitant changes in its processing enzymes in early stages of AD. Here, we aimed to investigate the effects of recombinant BRI2 ectodomain (rBRI2) on Aβ aggregation and on important molecular pathways involved in early stages of AD, including the unfolded protein response (UPR), phosphorylation and truncation of tau, as well as apoptosis. We found that rBRI2 delays Aβ fibril formation, although less efficiently than the BRI2 BRICHOS domain (BRI2 residues 113-231). In human neuroblastoma SH-SY5Y cells, rBRI2 slightly decreased cell viability and increased up to two-fold the Bax/Bcl-2 ratio and the subsequent activity of caspases 3 and 9, indicating activation of apoptosis. rBRI2 upregulated the chaperone BiP but did not modify the mRNA expression of other UPR markers (CHOP and Xbp-1). Strikingly, rBRI2 induced the activation of GSK3β but not the phosphorylation of tau. However, exposure to rBRI2 significantly induced the truncation of tau, indicating that BRI2 ectodomain can contribute to NFT formation. Since BRI2 can also regulate the metabolism of Aβ, the current data suggests that BRI2 ectodomain is a potential nexus between Aβ, tau pathology and neurodegeneration.


Related Articles

  • An effective treatment for Alzheimer's disease must consider both amyloid and tau. Lansdall, Claire J. // Bioscience Horizons: The National Undergraduate Research Journal;Jan2014, Vol. 7, p1 

    Alzheimer's disease (AD) is a devastating neurodegenerative disorder resulting in cognitive impairment, loss of executive functions and progressive dementia. AD is the most common cause of dementia and incidence is increasing, probably due to a rapidly ageing population. Despite research efforts...

  • FLZ Alleviates the Memory Deficits in Transgenic Mouse Model of Alzheimer’s Disease via Decreasing Beta-Amyloid Production and Tau Hyperphosphorylation. Bao, Xiu-Qi; Li, Ning; Wang, Tao; Kong, Xiang-Chen; Tai, Wen-Jiao; Sun, Hua; Zhang, Dan // PLoS ONE;Nov2013, Vol. 8 Issue 11, p1 

    Alzheimer’s disease (AD) is the most common cause of dementia worldwide and mainly characterized by the aggregated β-amyloid (Aβ) and hyperphosphorylated tau. FLZ is a novel synthetic derivative of natural squamosamide and has been proved to improve memory deficits in dementia...

  • Beta-Amyloid Impairs Reelin Signaling. Cuchillo-Ibáñez, Inmaculada; Balmaceda, Valeria; Botella-López, Arancha; Rabano, Alberto; Avila, Jesus; Sáez-Valero, Javier // PLoS ONE;Aug2013, Vol. 8 Issue 8, p1 

    Reelin is a signaling protein increasingly associated with the pathogenesis of Alzheimer’s disease that relevantly modulates tau phosphorylation. We have previously demonstrated that β-amyloid peptide (Aβ) alters reelin expression. We have now attempted to determine whether abnormal...

  • Twice is better: highlights of the second meeting focused on tau biology and pathology. Skoulakis, Efthimios M. C.; Amritpal Mudher // Biochemical Society Transactions;Aug2012, Vol. 40 Issue 4, p641 

    It is an exciting time for tau researchers as it is now generally accepted that abnormal tau species are required to mediate the toxic effects of amyloid β-peptide oligomers in Alzheimer's disease. Tau may play multiple roles in neurophysiology and there may be further pathologically relevant...

  • Brain Intraventricular Injection of Amyloid-β in Zebrafish Embryo Impairs Cognition and Increases Tau Phosphorylation, Effects Reversed by Lithium. Nery, Laura Roesler; Eltz, Natalia Silva; Hackman, Cristiana; Fonseca, Raphaela; Altenhofen, Stefani; Guerra, Heydi Noriega; Freitas, Vanessa Morais; Bonan, Carla Denise; Vianna, Monica Ryff Moreira Roca // PLoS ONE;Sep2014, Vol. 9 Issue 9, p1 

    Alzheimer’s disease (AD) is a devastating neurodegenerative disorder with no effective treatment and commonly diagnosed only on late stages. Amyloid-β (Aβ) accumulation and exacerbated tau phosphorylation are molecular hallmarks of AD implicated in cognitive deficits and synaptic...

  • Increased Phosphorylation of Tau and Synaptic Protein Loss in the Aged Transgenic Mice Expressing Familiar Alzheimer's Disease-Linked Presenilin 1 Mutation. Yang, Xifei; Yang, Ying; Liu, Jianjun; Li, Geng; Yang, Edward // Neurochemical Research;Jan2012, Vol. 37 Issue 1, p15 

    Mutations in presenilin 1 (PS-1) are associated with most early-onset familiar Alzheimer's disease (AD). Previous studies have demonstrated that PS-1 mutations enhance the production of beta-amyloid (Aβ). In this study, we further examined the in vivo effects of PS-1 mutation on tau and...

  • The Mechanism of Prevention and Treatment of Estrogen in Alzheimer's Disease. RAO Yan-qiu; WANG Wen-jun // Journal of International Obstetrics & Gynecology;Feb2014, Vol. 41 Issue 1, p32 

    Going with the social olden, the incidence rate of Alzheimer's disease increase evidently, the treatment become more important. More and more studies show that estrogen can prevent Alzheimer's disease. Estrogen can lower brain Aβ content, suppress tau phosphorylation, improve the...

  • Sex hormone-related neurosteroids differentially rescue bioenergetic deficits induced by amyloid-β or hyperphosphorylated tau protein. Grimm, Amandine; Biliouris, Emily; Lang, Undine; Götz, Jürgen; Mensah-Nyagan, Ayikoe; Eckert, Anne // Cellular & Molecular Life Sciences;Jan2016, Vol. 73 Issue 1, p201 

    Alzheimer's disease (AD) is an age-related neurodegenerative disease marked by a progressive cognitive decline. Metabolic impairments are common hallmarks of AD, and amyloid-β (Aβ) peptide and hyperphosphorylated tau protein-the two foremost histopathological signs of AD-have been...

  • Structural biology: Membrane enzyme cuts a fine figure. Wolfe, Michael S. // Nature;1/3/2013, Vol. 493 Issue 7430, p34 

    The article discusses the workings of presenilin enzymes malfunction, which separates proteins in cell membranes that can lead to Alzheimer's disease. It cites the two types of presenilin which include those that function as a single polypeptides and those that require other proteins for...

  • Autosomal dominant Alzheimer disease: a unique resource to study CSF biomarker changes in preclinical AD. Schindler, Suzanne Elizabeth; Fagan, Anne M. // Frontiers in Neurology;Jun2015, Vol. 6, p1 

    Our understanding of the pathogenesis of Alzheimer disease (AD) has been greatly influenced by investigation of rare families with autosomal dominant mutations that cause early onset AD. Mutations in the genes coding for amyloid precursor protein (APP), presenilin 1 (PSEN-1), and presenilin 2...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics